Medical Device | December 22, 2025
Abbott wins FDA & CE nod for groundbreaking premature infant heart device
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Patients with BRCA mutations often face aggressive disease and poor prognosis
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Subscribe To Our Newsletter & Stay Updated
